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Combined pulmonary ﬁbrosis and emphysema (CPFE) is a recently deﬁned syndrome, in which centrilobular and/or paraseptal
emphysemas in upper lung zones coexist with pulmonary ﬁbrosis in lower lobes in individuals. These patients have a characteristic
lung function proﬁle, with unexpected subnormal dynamic and static lung volumes, contrasting with a signiﬁcant reduction of
carbon monoxide transfer (DLco) and exercise hypoxemia. Pulmonary hypertension is highly prevalent in CPFE and is the leading
determinant of death. Tobacco smoking has been proposed as the main factor in its etiology, though the pathophysiology and
its natural history remain to be determined. High-resolution computed axial tomography is the mandatory tool to conﬁrm the
diagnosis. Currently, there is no consensus about its treatment since those published to date on this issue are limited to well-
characterised series of cases; hence, a better understanding of this entity may help in the development of future therapeutic
approaches.
1.Introduction
Pulmonary emphysema and idiopathic interstitial lung dis-
eases (ILDs) including idiopathic pulmonary ﬁbrosis (IPF)
are entities deﬁned by diﬀerent clinical, functional, radiolog-
ical, and pathological criteria [1]. IPF is the most common
ILD, occurring primarily in older adults, and associated
with the histopathologic and/or radiologic pattern of usual
interstitial pneumonia (UIP) [2]. Emphysema is deﬁned
as an enlargement of the air spaces distal to the terminal
bronchioles due to the destruction of the tissues forming
their walls [3]. Emphysema can cause an obstructive pattern
due to the diﬀerent structural changes occurring in the lung
[3–5].
Traditionally regarded as separate disease states, combi-
nation of both processes was described over 30 years ago by
Auerbach et al. [6] in a pathological study of 1824 autopsy
lungs. Even then, authors suggested that smoking could be
responsible for the coexistence of these processes, basing on
studies involving animal models exposed to tobacco smoke
[7, 8]. In early nineties, by means of high-resolution com-
puted axial tomography (HRCT), Wiggins et al. [9]r e p o r t e d
a correlation between functional and radiologic ﬁndings in 8
subjects with history of smoking who had severe dyspnea,
but whose pulmonary functional tests revealed no signs
of obstruction, normal static lung volumes, and depressed
DLCO. Imaging study showed that these patients had areas of
upper-lobepredominantemphysemaandlesionscompatible
with ﬁbrosis in both lung bases. In 2005, Cottin et al. char-
acterized this condition for the ﬁrst time as a well-
deﬁned syndrome termed “combined pulmonary ﬁbrosis
and emphysema” (CPFE) [1]. Since then, there is increasing
interest in this new entity, and several series, most with
a retrospective methodology, have been published in the
literature [10–25].
In this paper, we will review the particular features of
CFPE and also discuss some of the most recent evidence
published.2 Pulmonary Medicine
2. Epidemiology
The prevalence of CPFE is not known although it has been
estimated to represent between 5% and 10% of cases of
diﬀuse interstitial lung disease [26]. Most of the cohorts
studied have been men and generally present in people over
65 years of age who are active smokers or heavy ex-smokers
(over 40 pack years). Exposure to agricultural compounds
is another epidemiological data collected by some series
[1, 20, 27].
Recently, Cottin et al. [24] described the association of
CFPE with connective tissue diseases (CTDs). Several dif-
ferences were observed between this cohort and population
described in other series with CPFE. Although the majority
of patients with associated CTD had a similar smoking
history and similar function proﬁle compared with “classic
CPFE,” the populations studied were signiﬁcantly younger,
were more likely to be women, and tended to have less severe
outcomes. The predominant CTDs were rheumatoid arthri-
tis followed by systemic sclerosis and mixed connective tissue
disease. These observations should be explored in future
studies in order to analyse whether underlying inﬂammatory
disease also predisposes to the development of CFPE with
diﬀerent presentation.
Limitedbutinterestingepidemiologicaldataareavailable
about the relationship between CPFE and lung cancer. Usui
et al. [23] reported a high prevalence of CPFE in 1143 indi-
viduals with lung cancer. Speciﬁcally, CPFE was identiﬁed
in 101 cases (8.9%). These patients had a history of heavier
smoking and poorer prognosis than the ones without CPFE.
Similarly, Kitaguchi et al. [20] retrospectively reviewed the
records of 47 patients with CPFE and found that 22 of those
patients (46.8%) had lung cancer. Given that these ﬁndings
have been described in asiatic populations is unknown to
date if an ethnic or genetic component enhanced by smoking
exposure is also involved.
3.ClinicalCharacteristics
Exertionaldyspnea(functionalclassIIIorIVoftheNewYork
Heart Association) is the most common symptom among
patients. Physicalexamination usuallyrevealsbibasilarinspi-
ratory crackles and ﬁnger clubbing. Although less common,
other signs and symptoms reported are cough, wheezing,
perioral cyanosis, and asthenia [1, 13, 21, 26].
Pulmonary hypertension is a common and important
complication in the natural history of this syndrome, as it
is associated with a worse clinical course and lower survival
rates [1, 14, 26, 28]. Additionally, several authors have re-
ported a signiﬁcant prevalence of cardiovascular distur-
bances in these patients such a atherosclerotic artery disease
(coronary and peripheral) and left ventricular diastolic dys-
function on echocardiography [22].
4. Pathogenesis
Despite the lack of knowledge regarding the physiopatho-
logic substrate of CPFE, it can be supposed that it entails
a complex, overlapping process involving diﬀerent types of
cells, shared pathways, and mediators with an inﬂammatory
and/or ﬁbrogenic capacity. This process ﬁnally leads to the
destructionofthelungparenchymaandtheaberrantremod-
elling characteristic of lung ﬁbrosis. Furthermore, these cell
mediators interact with environmental factors which could
act as modiﬁers of the disease in the presence of a permissive
genotype. The role of tobacco smoking is suggested by its
demonstrated causative agent in both emphysema and IPF
[24]. Experimental studies in animal models are providing
information on the involvement of some inﬂammatory
mediators in the development of CPFE. The identiﬁcation
of molecular and genetic alterations involved in the etiology
of this syndrome through other methods (i.e., surgical lung
biopsies, explants from lobectomies) is needed, since it also
willprovideamoreeﬀectiveapproachforearlydiagnosisand
identifying molecular targets for future therapies.
4.1. Etiology. Cigarette smoking has been suggested as the
main etiologic factor, as a history of smoking is a constant
factor in all the cohorts reported [29]. Tobacco smoke, a
complex mix of over 4000 chemical substances, has been
associated with a wide range of diseases, and emphysema
is the lung disorder most commonly attributed to smoking
[30]. Kaolinite or aluminium silicate is an inorganic indus-
trial material found in tobacco smoke and which has been
isolated in alveolar macrophages of smoker patients with
lung emphysema and respiratory bronchiolitis with diﬀuse
interstitiallungdisease(RB/DILD)[31].Ithasbeenhypothe-
sizedthatmacrophageaccumulationafterchronicinhalation
of this mineral triggers the series of physiopathological
events that, in the end, lead to respiratory bronchiolitis and
emphysema [32].
Although the etiology of IPF is unknown, it is thought to
be a consequence of the interaction of environmental factors
in individuals with a genetic predisposition, with increasing
recognition of its association with smoking [33, 34]. In this
context, Katzenstein et al. [35] reported an unexpectedly
high frequency of ﬁbrosis in pieces of lung tissue removed
from smokers who were candidates for tumor surgery. These
patients showed no clinical evidence of interstitial lung
disease. It should be pointed out that smoking has also been
associated with a restrictive spirometric pattern in many
epidemiological studies [36], which supports the hypothesis
that smoking can produce diﬀerent types of eﬀects on
the lung parenchyma, as evidenced in diﬀerent phenotypic
expressions.
The association between CPFE and lung cancer may
reﬂect the susceptibility to chronic smoking-induced inﬂam-
mation, as shown in other studies on the relationship be-
tween COPD and IPF [23, 37, 38]. In addition, the high
prevalence of vasculopathy and pulmonary hypertension
describedinCPFEcanalsosupporttheroleofsmokinghabit
as pathogenetic factor, since it is a recognized risk factor in
the development of blood vessel disorders. The exposure of
endothelial cells of the pulmonary arteries to tobacco smoke
extract has been shown to cause an irreversible inhibition
of endothelial nitric oxide synthase (eNOS) activity due
to a reduction in its protein content and messenger RNA.
This inhibition of eNOS activity due to tobacco smoke mayPulmonary Medicine 3
explain the decreased expression in pulmonary arteries seen
in smokers and may predispose patients to greaterchanges in
the pulmonary vessels [39].
4.2. Oxidative Stress. Increases in oxidative and nitrosative
stress have been postulated as mechanisms potentially in-
volved in the development of CPFE; they increase inﬂam-
matory-cell(leukocyte)activation,whichcontributestolocal
and systemic increases in oxidant levels. The production of
an excess of oxidants that are not neutralized by the body’s
antioxidant systems causes structural changes in epithelial,
vascular, and connective tissues [35].
4.3. Metalloproteinases. Metalloproteinases (MMPs) consti-
tute a family of enzymes produced by alveolar epithelial
cells, macrophages, and neutrophils, which participate in
emphysema development due to their signiﬁcant proteolytic
activity and collagen-degrading ability. The expression of
MMP activity is modulated by several cytokines, including
interleukin 13 (IL 13), which, in experimental models, is
able to produce enlarged airway spaces, ﬁbrosis, and inﬂam-
matory remodelling of the airways [40] .Ar e c e n ts t u d y
in a subgroup of CPFE patients reported an increase in
the expression of some MMPs in the areas aﬀected by a
combination of emphysema and UIP, suggesting that these
proteins also have a role in extracellular matrix deposition
and anomalous tissue remodelling— a characteristic hall-
mark of the process of lung ﬁbrosis [30].
4.4. Caveolin-1. Caveolae are invaginations of the cell mem-
brane in various types of cells. They are rich in proteins,
lipids, and cholesterol and are formed and maintained by
proteins called caveolins and caveolin-1 being the most
studied. This protein is a potent immunomodulator, and
it has been ascribed several functions, including signal
transduction, the mediation of cell apoptosis, intracellular
calcium and eNOS regulation, and the suppression of
tumours [41, 42]. Lung tissue expresses high levels of
caveolins, and dysfunctions have been linked to pulmonary
hypertension associated with COPD and emphysema, inter-
stitial ﬁbrosis, and lung cancer. As a result, caveolin-1 may
be another important mediator in the etiology of CPFE,
and it undoubtedly deserves to be the subject of further
investigations [43].
4.5. Genetic Factors. Mutations in the surfactant protein C
(SFTPC) gene have been mostly associated with interstitial
lung disease [44]. Cottin et al. [45]r e c e n t l yr e p o r t e da
dominant mutation in the SFTPC gene in a young non-
smoking female with CPFE and in her infant with interstitial
lungdisease.ThepathophysiologyofSP-C-associateddisease
involves the dysfunction of surfactant homeostasis, causing
injury or death of alveolar epithelial type II cells and myoﬁ-
broblast proliferation. A process of genetically mediated
alveolar injury may conceivably contribute to emphysema
in addition to inﬂammation and ﬁbrosis, and thus to the
CPFE phenotype. This ﬁrst paper supports the hypothesis
that patients with CPFE syndrome may have an underlying
genetic predisposition.
4.6. Animal Models. Three studies using animal models have
managed to reproduce the histopathological elements of
CPFE. The ﬁrst, performed by Hoyle et al. [46], showed
that the overexpression of platelet-derived growth factor
(PDGF) led to the enlargement of airway spaces, and
inﬂammation and ﬁbrosis in the lungs of transgenic mice.
PDGF is a growth factor and has a pleiotropic eﬀect on
several lines of cells and is involved in the pathogenesis of
both IPF and emphysema. This dual action may be due
to its mitogenic activity on ﬁbroblasts, its interaction with
diﬀerent inﬂammatory markers, and its probable capacity to
induce a protease/antiprotease imbalance in the extracellular
matrix,whichwouldtriggerthedevelopmentofemphysema.
Overexpression of other mediators in the lungs, such
as tumor necrosis factor-alpha (TNF-α) and transforming
growth factor-beta (TGF-β), has also generated this complex
phenotype of ﬁbrosis and emphysema in research animals
[47, 48]. TNF-α is a multifunctional cytokine with some
apparent proﬁbrotic activity and is considered an important
mediator of various pulmonary and systemic symptoms
in diverse respiratory diseases [49]. Smoking causes this
cytokine to be released into the lungs, both in humans and
animal models, and high levels have been found in the
sputum and peripheral blood of COPD patients [50].
TGF-β is one of the most potent proﬁbrogenic mediators
known to play a role in the pathogenesis of IPF. The TGF-β1
isoform induces the diﬀerentiation of ﬁbroblasts into myoﬁ-
broblasts, the transition of epithelial cells into ﬁbroblasts,
and the synthesis of molecules of the extracellular matrix,
as well as promoting the apoptosis of alveolar epithelial
cells [49]. Its role in the development of emphysema is less
clear although an increase in its expression in the bronchial
epithelium and in the macrophages of the small airways has
been observed in COPD patients [51]. In summary, TGF-
β is an important mediator during the transition from the
immune inﬂammatory response to the tissue remodelling
process [52, 53].
5.Diagnosis
5.1. Imaging Studies. A simple chest X-ray reveals an inter-
stitial pattern or reticulonodular inﬁltrates in both lung
bases and the subpleural region, and hyperlucency in the
apices with thinning of pulmonary vessels and a reduction
in their number. (Figure 1). However, the radiologic ﬁndings
for this entity may go unnoticed in a chest X-ray, so
HRCT scanning is the most appropriate technique for
conﬁrming diagnosis. (Figure 2) Cottin et al. [1]d e s c r i b e d
the following radiologic criteria to determine the CFPE:
ﬁrstly, the presence of emphysema on HRCT, deﬁned as well-
demarcated areas of decreased attenuation in comparison
with contiguous normal lung and marginated by a very
thin (<1mm) wall or no wall, and/or multiple bullae
(>1cm) with upper zone predominance, and secondly, the
presence of diﬀuse parenchymal lung disease with signiﬁcant
pulmonary ﬁbrosis on HRCT, deﬁned as reticular opacities
with peripheral and basal predominance, honeycombing,
architectural distortion, and/or traction bronchiectasis or
bronchiolectasis; focal ground-glass opacities and/or areas of4 Pulmonary Medicine
Figure 1: Chest X-ray of a patient diagnosed with combined pul-
monary ﬁbrosis and emphysema demonstrating bilateral interstitial
pattern, predominantly right sided, with reticulonodular inﬁltrates
in the lung bases and subpleural region, and a reduction of lung
density in upper lung ﬁelds, mainly on the left.
alveolar condensation may be associated but should not be
prominent. The emphysematous lesions should be graded as
ape r c e ntageo faﬀectedlung,whichhastobemorethan10%
[14].
Centrilobular emphysema and/or bullous emphysema
are present in the upper zones in most of published cohorts,
and their association with paraseptal emphysema (low-
attenuation areas in subpleural zone) has been described in
90% of cases. Hence, some authors suggest that it is a typical
feature of CPFE [1, 26, 54, 55].
In some cases, distinguishing images of emphysema from
those of ﬁbrosis is a complex task as a transition area can
be observed between both regions, making it diﬃcult to
interpret them correctly [55]. For instance, emphysematous
changes or cysts surrounding ground-glass opacity may be
mistaken for honeycomb cysts [56]. Brillet and colleagues
[55] identiﬁed three HRCT patterns in 61 patients with
CFPE: (1) progressive transition (n = 23,38%) with diﬀuse
emphysema (centrilobular and/or bullous) and zone of
transition between bullae and honeycombing; (2) paraseptal
emphysema (n = 13,21%) with predominant subpleural
bullae of enlarging size at the bases; (3) separate processes
(n = 14,23%) with independent areas of ﬁbrosis and
emphysema. Eleven patients (18%) could not be classiﬁed.
The wide variety of radiological signs present in the
HRCT scans correlates closely with histopathological data.
UIP is the most common pattern, but lesions have also been
reported which are compatible with nonusual interstitial
pneumonia,tobacco-relatedILD,orevenotherunclassiﬁable
ﬁbrotic lung disease [15]. Given this pathologic heterogene-
ity, some authors advocate for the nonrequirement of a
speciﬁc histopathologic pattern as a diagnostic criterion of
CPFE [22].
5.2. Lung Function and Gas Exchange. The coexistence of
emphysema and ﬁbrosis leads to a characteristic functional
proﬁle which is in direct contrast to the degree of dyspnea
suﬀeredbythesepatients.Forcedvitalcapacity(FVC),forced
expiratory volume in the ﬁrst second (FEV1), and total
lung capacity (TLC) are usually within unexpected normal
ranges or only slightly abnormal, unlike DLCO,w h i c hi s
signiﬁcantly reduced. Hypoxemia is a common ﬁnding; it
is generally moderate at rest and gets worse during exercise
[1, 17, 26]. Hyperinﬂation and an increase in pulmonary
compliance due to the loss of elasticity in the areas with
emphysema probably compensate for the loss of volume
caused by ﬁbrosis [16–18]. In contrast, the overlapping of
both pathologies could exert a negative synergic eﬀect on
gas exchange, resulting in a severe decrease in DLCO. This
particular functional pattern leads to at least 2 important
clinical repercussions: ﬁrstly, the presence of normal lung
volumes does not exclude the diagnosis of pulmonary ﬁ-
brosis, and secondly, neither FVC nor TLC can be used as
parameters to monitor the disease, as they do not reﬂect
the degree of functional impairment. In this instance, DLCO
is the variable which best correlates with the degree of
parenchymal destruction. However, a low DLCO can also
reﬂect disorders in the pulmonary vascular bed, speciﬁcally
pulmonary hypertension (PH), as it is a highly prevalent
condition in this entity.
5.3.PulmonaryHypertension. PHisacommoncomplication
during the clinical course of CPFE and is the main condition
that inﬂuents its evolution and prognosis [1, 14, 26, 28]. The
prevalencereportedinthesepatientsvariesbetween47%and
90% and is much higher than in COPD or IPF alone [57]. In
most published series, the diagnosis of PH was established
by a transthoracic echocardiogram. PH was deﬁned by an
estimated systolic pressure in the pulmonary artery (eSPAP)
≥ 45mm Hg. In the study by Cottin et al. [1], the presence of
PH was an independent predictor of mortality, with a hazard
ratio of 4.03 (P = .03). The 5-year probability of survival
was 25% in patients with PH diagnosed by echocardiogram
compared with 75% in those with no signs of PH at the time
of diagnosis. The mean survival time in this series was 6.1
years, dropping to 3.9 years in those patients with associated
PH.
Mej´ ıa et al. [14] recently published a study in which
diﬀerent clinical, functional, and prognostic variables were
compared in a group of patients with CPFE and another
with IPF and with no evidence of emphysema. Using a
logistic regression model, they showed that, together with
the FVC, an eSPAP ≥ 75mmHg was one of the main
variables determining survival. In these patients, the extent
of the emphysema established by HRCT showed a positive
correlation with eSPAP.
The signiﬁcant eﬀect of pulmonary hemodynamics on
mortality in this syndrome was shown in another study
performed by Cottin and colleagues [28], involving 40
patients with CPFE who had PH conﬁrmed by right heart
catheterization. The factors associated with a worse prog-
nosis were increased pulmonary vascular resistance, reduced
cardiac index, a high heart rate, and low DLCO. In this study,
the diagnosis of PH was established at a mean of 16 months
after the initial diagnosis of CPFE, and the estimated survival
rate at 1 year in this cohort was 60%.
Therefore,routinescreeningofthesepatientsforPHwith
Doppler echocardiography would be justiﬁed given its highPulmonary Medicine 5
(a) (b)
(c) (d)
Figure 2: High-resolution computerized tomography (HRCT) of the same patient. (a) Presence of paraseptal emphysema and subpleural
bullae (white arrowheads) and centrilobular emphysema (arrows) in both upper lobes. (b) Reticular interstitial disease with intralobular
thickening and images of subpleural honeycombing and traction bronchiectasis (black arrowheads), (c) Reticular interstitial disease in
middle and right lower lobes, with interlobular septal thickening, subpleural honeycombing, and traction bronchiectasis. (d) Coronal
reconstruction in the posterior regions of both lungs: bilateral paraseptal emphysema (white arrowheads) and reticular interstitial disease
and honeycombing in right lower lobe.
prevalence and its important role in the prognosis. It should
be noted that most recent updated clinical classiﬁcation of
PH includes CPFE in the group 3 (owing to lung diseases
and/or hypoxia) under the term “Other pulmonary diseases
with mixed restrictive and obstructive pattern” [58].
T h ep r e s e n c eo fe m p h y s e m ac a nm a k ed i ﬃcult inter-
pretation of echocardiographic studies, so some authors
propose assessing alternative diagnostic techniques such as
magnetic resonance imaging (MRI). MRI ﬂow mapping
shows good correlations with hemodynamic parameters [59,
60]. However, general access and use of this technique in this
ﬁeld is still very limited.
6. Treatment
The therapeutic options for CPFE are limited. Treatment
with systemic corticosteroids and immunomodulator ther-
apy, similar to that for treating IPF, has been used, but
without beneﬁcial results in the published series. Smoking
cessation is a sensible measure that probably halts the pro-
gression of emphysema lesions. Oxygen therapy is appropri-
ate for management of hypoxemia.The possibility of using
the speciﬁc therapy approved for treating pulmonary arterial
hypertension (endothelin-1 receptor antagonists, prostan-
oids, or phosphodiesterase type 5 inhibitors), as has been
testedinCOPDorIPF,hasbeenconsideredbysomeauthors.
However, no studies have been published to date on this
issue. It is important to point out that the presence of
emphysema and abnormal changes in pulmonary vascular
bed in these patients may be associated with an imbal-
ance in the ventilation/perfusion ratio (V/Q), as hypoxic
vasoconstriction is one of the main mechanisms to avoid
worsening arterial oxygenation. These vasodilator drugs can
worsen hypoxemia by inhibiting this mechanism. Thus,
appropriately designed trials are necessary to study the eﬀect
of these drugs on gas exchange in these patients.6 Pulmonary Medicine
7. Conclusions
The growing number of published papers about CPFE
demonstrates the increasing interest in this phenotype,
which encompasses a particular clinical, functional, and
radiological proﬁle. Associated PH is a common complica-
tion that it is important to identify, as it is the principal
determinant of reduced survival in these patients. The over-
lapping of a wide variety of radiological and histopathologic
lesions described in this syndrome supports the hypothesis
that smoking habit as the main etiologic factor involved can
generate diverse lung parenchymal disorders with diﬀerent
phenotypic expressions. Better understanding of its phys-
iopathology and the molecular mechanisms involved will
make it possible to develop future therapeutic strategies. It
should not be forgotten that the prevention and treatment
of smoking would possibly have the major impact on the
natural history of this entity.
Acknowledgment
The authors would like to thank Dr. Ignasi Guasch for his
constant support and for providing the radiological images.
References
[1] V. Cottin, H. Nunes, P. Y. Brillet et al., “Combined pulmonary
ﬁbrosis and emphysema: a distinct underrecognised entity,”
EuropeanRespiratoryJournal,vol.26,no.4,pp.586–593,2005.
[ 2 ]G .R a g h u ,H .R .C o l l a r d ,J .J .E g a ne ta l . ,“ A nO ﬃcial ATS/
ERS/JRS/ALAT Statement: idiopathic pulmonary ﬁbrosis: ev-
idence-based guidelines for diagnosis and management,”
American Journal of Respiratory and Critical Care Medicine,
vol. 183, no. 6, pp. 788–824, 2011.
[3] B. R. Celli, W. MacNee, A. Agusti et al., “Standards for the
diagnosis and treatment of patients with COPD: a summary
of the ATS/ERS position paper,” European Respiratory Journal,
vol. 23, no. 6, pp. 932–946, 2004.
[4] L. N´ u˜ nez-Naveira, C. Montero-Mart´ ınez, and D. Ramos-Bar-
b´ on, “Oxidation, inﬂammation and structural modiﬁcations,”
Archivos de Bronconeumologia, vol. 43, no. 1, pp. 18–29, 2007.
[5] A. A. Zeki, M. Schivo, A. L. Chan et al., “Geoepidemiology of
COPD and idiopathic pulmonary ﬁbrosis,” Journal of Autoim-
munity, vol. 34, no. 3, pp. J327–J338, 2010.
[6] O. Auerbach, L. Garﬁnkel, and E. C. Hammond, “Relation of
smoking and age to ﬁndings in lung parenchyma: a micro-
scopic study,” Chest, vol. 65, no. 1, pp. 29–35, 1974.
[7] J. A. Hernandez, A. E. Anderson, W. L. Holmes, and A. G.
Foraker, “Pulmonary parenchymal defects in dogs following
prolonged cigarette smoke exposure,” American Review of Re-
spiratory Disease, vol. 93, no. 1, pp. 78–83, 1966.
[8] E. C. Hammond, O. Auerbach, D. Kirman, and L. Garﬁnkel,
“Eﬀects of cigarette smoking on dogs,” Archives of Environ-
mental Health, vol. 21, no. 6, pp. 740–753, 1970.
[9] J.Wiggins,B.Strickland,andM.Turner-Warwick,“Combined
cryptogenic ﬁbrosing alveolitis and emphysema: the value of
high resolution computed tomography in assessment,” Respi-
ratory Medicine, vol. 84, no. 5, pp. 365–369, 1990.
[10] M. J. Doherty, M. G. Pearson, E. A. O’Grady, V. Pellegrini,
and P. M. A. Calverley, “Cryptogenic ﬁbrosing alveolitis with
preserved lung volumes,” Thorax, vol. 52, no. 11, pp. 998–
1002, 1997.
[11] A. Grubstein, D. Bendayan, I. Schactman, M. Cohen, D.
Shitrit, and M. R. Kramer, “Concomitant upper-lobe bullous
emphysema, lower-lobe interstitial ﬁbrosis and pulmonary
hypertension in heavy smokers: report of eight cases and re-
view of the literature,” Respiratory Medicine, vol. 99, no. 8, pp.
948–954, 2005.
[ 1 2 ] D .R .S i l v a ,M .B .G a z z a n a ,M .M .K n o r s t ,a n dS .S .M .B a rr e t o ,
“Idiopathic pulmonary ﬁbrosis and emphysema in smokers,”
Jornal Brasileiro de Pneumologia, vol. 34, no. 10, pp. 779–786,
2008.
[13] M.Kosacka,A.Brzecka,R.Jankowska,J.Lewczuk,E.Mroczek,
and B. Wery˜ nska, “Combined pulmonary ﬁbrosis and emphy-
sema -case report and literature review,” Pneumonologia i
Alergologia Polska, vol. 77, no. 2, pp. 205–210, 2009.
[14] M. Mej´ ıa, G. Carrillo, J. Rojas-Serrano et al., “Idiopathic
pulmonary ﬁbrosis and emphysema: decreased survival asso-
ciated with severe pulmonary arterial hypertension,” Chest,
vol. 136, no. 1, pp. 10–15, 2009.
[15] M. D. Jankowich, M. Polsky, M. Klein, and S. Rounds, “Het-
erogeneity in combined pulmonary ﬁbrosis and emphysema,”
Respiration, vol. 75, no. 4, pp. 411–417, 2008.
[16] J. P. Casas, H. Abbona, A. Robles, and A. M. Lopez, “Normal
lung volumes in patients with idiopathic pulmonary ﬁbrosis
and emphysema,” Medicina, vol. 68, no. 4, pp. 282–284, 2008.
[17] J. F. Aduen, D. A. Zisman, S. I. Mobin et al., “Retrospective
study of pulmonary function tests in patients presenting
with isolated reduction in single-breath diﬀusion capacity:
implications for the diagnosis of combined obstructive and
restrictive lung disease,” Mayo Clinic Proceedings, vol. 82, no.
1, pp. 48–54, 2007.
[ 1 8 ]M .M u r a ,M .Z o m p a t o r i ,A .M .G .P a c i l l i ,L .F a s a n o ,M .
Schiavina, and M. Fabbri, “The presence of emphysema fur-
ther impairs physiologic function in patients with idiopathic
pulmonary ﬁbrosis,” Respiratory Care, vol. 51, no. 3, pp. 257–
265, 2006.
[19] T. Akagi, T. Matsumoto, T. Harada et al., “Coexistent emphy-
sema delays the decrease of vital capacity in idiopathic pulmo-
nary ﬁbrosis,” Respiratory Medicine, vol. 103, no. 8, pp. 1209–
1215, 2009.
[20] Y. Kitaguchi, K. Fujimoto, M. Hanaoka, S. Kawakami, T. Hon-
da, and K. Kubo, “Clinical characteristics of combined pul-
monary ﬁbrosis and emphysema,” Respirology, vol. 15, no. 2,
pp. 265–271, 2010.
[21] S. C. Arce, L. Molinari, and E. L. De Vito, “Functional respir-
atory evolution in two patients with emphysema and pulmo-
nary ﬁbrosis,” Medicina, vol. 69, no. 3, pp. 350–352, 2009.
[22] M.D.JankowichandS.Rounds,“Combinedpulmonaryﬁbro-
sis and emphysema alters physiology but has similar mortality
to pulmonary ﬁbrosis without emphysema,” Lung, vol. 188,
no. 5, pp. 365–373, 2010.
[23] K. Usui, C. Tanai, Y. Tanaka, H. Noda, and T. Ishihara, “The
prevalence of pulmonary ﬁbrosis combined with emphysema
in patients with lung cancer,” Respirology,v o l .1 6 ,n o .2 ,p p .
326–331, 2011.
[24] V. Cottin, H. Nunes, L. Mouthon et al., “Combined pul-
monary ﬁbrosis and emphysema syndrome in connective tis-
sue disease,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 295–
304, 2011.
[25] N. W. Todd, J. Jeudy, S. Lavania et al., “Centrilobular emphy-
sema combined with pulmonary ﬁbrosis results in improved
survival,” Fibrogenesis and Tissue Repair, vol. 4, no. 1, article 6,
2011.
[26] V. Cottin, P.-Y. Brillet, H. Nunes, and J.-F. Cordier, “recherche
sur les maladies “orphelines” pulmonaires (GERM“O”P).Pulmonary Medicine 7
Combined pulmonary ﬁbrosis and emphysema,” Presse Medi-
cale, vol. 36, no. 6, pp. 936–944, 2007.
[27] Z. Daniil, A. Koutsokera, and K. Gourgoulianis, “Combined
pulmonary ﬁbrosis and emphysema in patients exposed to
agrochemical compounds,” European Respiratory Journal, vol.
27, no. 2, article 434, 2006.
[28] V. Cottin, J. Le Pavec, G. Pr´ evot et al., “Pulmonary hyper-
tension in patients with combined pulmonary ﬁbrosis and
emphysema syndrome,” European Respiratory Journal, vol. 35,
no. 1, pp. 105–111, 2010.
[29] K. Portillo Carroz and J. Rold´ an S´ anchez, “Combination of
pulmonary ﬁbrosis and emphysema: is tobacco once again
the protagonist?” Medicina Clinica, vol. 136, no. 1, pp. 18–20,
2010.
[30] P. Rogliani, M. Mura, P. Mattia et al., “HRCT and histopatho-
logical evaluation of ﬁbrosis and tissue destruction in IPF
associated with pulmonary emphysema,” Respiratory Medicin-
e, vol. 102, no. 12, pp. 1753–1761, 2008.
[31] E. Mons´ o ,J .M .T u r a ,M .M a r s a l ,F .M o r e l l ,J .P u j a d a s ,a n d
J. Morera, “Mineralogical microanalysis of idiopathic pul-
monaryﬁbrosis,”ArchivesofEnvironmentalHealth,vol.45,no.
3, pp. 185–188, 1990.
[32] C. E. Girod and T. E. King Jr., “COPD: a dust-induced dis-
ease?” Chest, vol. 128, no. 4, pp. 3055–3064, 2005.
[33] K. M. Antoniou, D. M. Hansell, M. B. Rubens et al., “Idio-
pathic pulmonary ﬁbrosis: outcome in relation to smoking
status,” American Journal of Respiratory and Critical Care
Medicine, vol. 177, no. 2, pp. 190–194, 2008.
[34] V. S. Taskar and D. B. Coultas, “Is idiopathic pulmonary ﬁbro-
sis an environmental disease?” Proceedings of the American
Thoracic Society, vol. 3, no. 4, pp. 293–298, 2006.
[35] A. L. A. Katzenstein, S. Mukhopadhyay, C. Zanardi, and E.
Dexter, “Clinically occult interstitial ﬁbrosis in smokers: clas-
siﬁcation and signiﬁcance of a surprisingly common ﬁnding
in lobectomy specimens,” Human Pathology,v o l .4 1 ,n o .3 ,p p .
316–325, 2010.
[36] D.J.Lederer,P.L.Enright,S.M.Kawutetal.,“Cigarettesmok-
ingisassociatedwithsubclinicalparenchymallungdisease:the
Multi-Ethnic Study of Atherosclerosis (MESA)-lung study,”
American Journal of Respiratory and Critical Care Medicine,
vol. 180, no. 5, pp. 407–414, 2009.
[37] R. P. Young, R. J. Hopkins, T. Christmas, P. N. Black, P.
Metcalf, and G. D. Gamble, “COPD prevalence is increased
in lung cancer, independent of age, sex and smoking history,”
EuropeanRespiratoryJournal,vol.34,no.2,pp.380–386,2008.
[38] R. Hubbard, A. Venn, S. Lewis, and J. Britton, “Lung cancer
and cryptogenic ﬁbrosing alveolitis: a population-based co-
hort study,” American Journal of Respiratory and Critical Care
Medicine, vol. 161, no. 1, pp. 5–8, 2000.
[39] J. A. Barber` a, V. I. Peinado, S. Santos, J. Ramirez, J. Roca,
and R. Rodriguez-Roisin, “Reduced expression of endothelial
nitricoxidesynthaseinpulmonaryarteriesofsmokers,”Amer-
ican Journal of Respiratory and Critical Care Medicine, vol. 164,
no. 4, pp. 709–713, 2001.
[40] P. C. Fulkerson, C. A. Fischetti, L. M. Hassman, N. M. Niko-
laidis, and M. E. Rothenberg, “Persistent eﬀects induced by
IL-13 in the lung,” American Journal of Respiratory Cell and
Molecular Biology, vol. 35, no. 3, pp. 337–346, 2006.
[41] R. Gosens, M. Mutawe, S. Martin et al., “Caveolae and Cave-
olins in the respiratory system,” Current Molecular Medicine,
vol. 8, no. 8, pp. 741–753, 2008.
[42] L. C. Huber, A. Soltermann, M. Fischler et al., “Caveolin-
1 expression and hemodynamics in COPD patients,” Open
Respiratory Medicine Journal, vol. 3, pp. 73–78, 2009.
[43] K. Portillo Carroz, J. Rold´ an S´ anchez, and J. Morera Prat,
“Combined pulmonary ﬁbrosis and emphysema,” Archivos de
Bronconeumologia, vol. 46, no. 12, pp. 646–651, 2010.
[44] L. M. Nogee, A. E. Dunbar, S. E. Wert, F. Askin, A. Hamvas,
and J. A. Whitsett, “A mutation in the surfactant protein C
geneassociatedwithfamilialinterstitiallungdisease,”TheNew
EnglandJournalofMedicine,vol.344,no.8,pp.573–579,2001.
[45] V. Cottin, P. Reix, C. Khouatra, F. Thivolet-B´ ejui, D. Feld-
mann, and J.-F. Cordier, “Combined pulmonary ﬁbrosis and
emphysema syndrome associated with familial SFTPC muta-
tion,” Thorax, vol. 66, no. 10, pp. 918–919, 2011.
[46] G. W. Hoyle, J. Li, J. B. Finkelstein et al., “Emphysematous
lesions, inﬂammation, and ﬁbrosis in the lungs of transgenic
mice overexpressing platelet-derived growth factor,” American
Journal of Pathology, vol. 154, no. 6, pp. 1763–1775, 1999.
[47] L. K. A. Lundblad, J. Thompson-Figueroa, T. Leclair et al.,
“Tumor necrosis factor-α overexpression in lung disease: a
single cause behind a complex phenotype,” American Journal
of Respiratory and Critical Care Medicine, vol. 171, no. 12, pp.
1363–1370, 2005.
[48] G. L. Chun, S. Cho, R. J. Homer, and J. A. Elias, “Genetic con-
trol of transforming growth factor-β1-induced emphysema
and ﬁbrosis in the murine lung,” Proceedings of the American
Thoracic Society, vol. 3, no. 6, pp. 476–477, 2006.
[49] M. Selman, C. Navarro, and M. Gaxiola, “Idiop´ atica pul-
monary Fibrosis: in search of an eﬀective treatment,” Archivos
de Bronconeumologia, vol. 41, no. 5, pp. 15–20, 2005.
[50] C. Casanova Macario, J. P. D. T. Tajes, and M. M. De Oca,
“Systemic involvement and prognostic factors,” Archivos de
Bronconeumologia, vol. 43, no. 3, pp. 25–34, 2007.
[51] E. Ant´ on D´ ıaz, D. R. L´ opez, and J. A. Berm´ udez, “Inheritance
and environment in chronic obstructive pulmonary disease,”
Archivos de Bronconeumologia, vol. 43, supplement 1, pp. 10–
17, 2007.
[52] H. Takizawa, M. Tanaka, K. Takami et al., “Increased expres-
sion of transforming growth factor-β1i ns m a l la i r w a ye p -
ithelium from tobacco smokers and patients with chronic
obstructive pulmonary disease (COPD),” American Journal of
Respiratory and Critical Care Medicine, vol. 163, no. 6, pp.
1476–1483, 2001.
[53] G. Peces-Barba Romero, “Etiopatogenia of the aerial atra-
pamiento in the EPOC,” Archivos de Bronconeumologia, vol.
41, supplement 3, pp. 9–17, 2005.
[54] A. K. Attili, E. A. Kazerooni, B. H. Gross, K. R. Flaherty, J.
L. Myers, and F. J. Martinez, “Smoking-related interstitial
lungdisease:radiologic-clinical-pathologiccorrelation,” Radi-
ographics, vol. 28, no. 5, pp. 1383–1398, 2008.
[55] P. Y. Brillet, V. Cottin, P. Letoumelin et al., “Combined apical
emphysema and basal ﬁbrosis syndrome (emphysema/ﬁbrosis
syndrome): CT imaging features and pulmonary function
tests,” Journal de Radiologie, vol. 90, no. 1, pp. 43–51, 2009.
[56] M. Akira, Y. Inoue, M. Kitaichi, S. Yamamoto, T. Arai, and
K. Toyokawa, “Usual interstitial pneumonia and nonspeciﬁc
interstitial pneumonia with and without concurrent emphy-
sema: thin-section CT ﬁndings,” Radiology, vol. 251, no. 1, pp.
271–279, 2009.
[57] N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut,
“Pulmonary hypertension in idiopathic pulmonary ﬁbrosis,”
Chest, vol. 132, no. 3, pp. 998–1006, 2007.
[58] N. Gali` e, M. M. Hoeper, M. Humbert et al., “Guidelines for
the diagnosis and treatment of pulmonary hypertension,” Eu-
ropeanRespiratoryJournal,vol.34,no.6,pp.1219–1263, 2009.
[59] G. Sergiacomi, F. Bolacchi, M. Cadioli et al., “Combined
pulmonary ﬁbrosis and emphysema: 3D time-resolved MR8 Pulmonary Medicine
angiographic evaluation of pulmonary arterial mean transit
time and time to peak enhancement,” Radiology, vol. 254, no.
2, pp. 601–608, 2010.
[60] V. Fuster and J. Sanz, “Pulmonary hypertension: new insights
from techniques imaging,” Revista Espanola de Cardiologia,
vol. 60, supplement 3, pp. 2–9, 2007.